Manipal Education and Medical Group has participated in a round that took the total raised by the healthcare product and access platform to $53m.

Rare disease therapy developer Homology Medicines has raised approximately $130m in VC funding from investors including Novartis.

Celgene has paid biotech startup Vividion $101m up front in a strategic partnership that includes an equity investment of undisclosed size.

Eye disease therapy developer ViewPoint Therapeutics has completed a Rise Fund-led series B round featuring Novo, two years after its $4m series A.

Itochu Technology Ventures, Dai-ichi Life, Saison Ventures, Mizuho Capital and Mitsubishi UFJ Capital have all invested in the medical access app developer.